Because early trial data indicate that tralokinumab may be less likely to drive AOEs compared with dupilumab, for the same indications, a careful examination of real-world evidence will be necessary to establish this and whether IL-4, IL-13, or both are the drivers for the conjunctivitis observed.26–28,48–50,52. Here, IL4 is linked to conjunctivitis.